Ovid Therapeutics (OVID) Stock Price, News & Analysis

Company Overview

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Key Stats

• Today's Range: $0.31 to $0.35
• 50-Day Range: $0.26 to $0.35
• 52-Week Range: $0.24 to $3.31
• Volume: 1.22 million shs
• Average Volume: 502,476 shs
• Market Capitalization: $23.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.78
• Consensus Rating: Buy

Ovid Therapeutics Stock Analysis - MarketRank™

Ovid Therapeutics scored higher than 84% of companies evaluated by MarketBeat, and ranked 297th out of 1,886 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Ovid Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Ovid Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Ovid Therapeutics are expected to decrease in the coming year, from ($0.40) to ($0.64) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ovid Therapeutics is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ovid Therapeutics is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ovid Therapeutics has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.74% of the float of Ovid Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Ovid Therapeutics has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Ovid Therapeutics has recently increased by 21.64%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ovid Therapeutics does not currently pay a dividend.

Dividend Growth

Ovid Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.85

Percentage of Shares Shorted

2.74% of the float of Ovid Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Ovid Therapeutics has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Ovid Therapeutics has recently increased by 21.64%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.33

News Sentiment

Ovid Therapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Ovid Therapeutics this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for OVID on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Ovid Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ovid Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.10% of the stock of Ovid Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

72.24% of the stock of Ovid Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OVID Stock Analysis - Frequently Asked Questions

How have OVID shares performed this year?

Ovid Therapeutics' stock was trading at $0.9337 on January 1st, 2025. Since then, OVID stock has decreased by 64.5% and is now trading at $0.3312.
View the best growth stocks for 2025 here.

How were Ovid Therapeutics' earnings last quarter?

Ovid Therapeutics Inc. (NASDAQ:OVID) announced its earnings results on Tuesday, May, 13th. The company reported ($0.14) EPS for the quarter, hitting analysts' consensus estimates of ($0.14). The company earned $0.13 million during the quarter, compared to analysts' expectations of $0.03 million. Ovid Therapeutics had a negative net margin of 5,142.56% and a negative trailing twelve-month return on equity of 39.24%.

When did Ovid Therapeutics IPO?

Ovid Therapeutics (OVID) raised $80 million in an IPO on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

Who are Ovid Therapeutics' major shareholders?

Top institutional shareholders of Ovid Therapeutics include Acadian Asset Management LLC (2.94%), Adage Capital Partners GP L.L.C. (1.62%), Affinity Asset Advisors LLC (0.94%) and Assenagon Asset Management S.A. (0.79%). Insiders that own company stock include Jeremy M Levin, Margaret A Alexander and Jason Tardio.
View institutional ownership trends.

How do I buy shares of Ovid Therapeutics?

Shares of OVID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ovid Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ovid Therapeutics investors own include Plug Power (PLUG), Alamos Gold (AGI), FuelCell Energy (FCEL), KALA BIO (KALA), Lipocine (LPCN), Fortress Biotech (FBIO) and Workhorse Group (WKHS).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 6/09/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OVID
• CIK: 1636651
• Web: www.ovidrx.com
• Phone: (646) 661-7661
• Fax: N/A
• Employees: 60
• Year Founded: 2014

Price Target and Rating

• Average Stock Price Target: $2.78
• High Stock Price Target: $4.00
• Low Stock Price Target: $1.20
• Potential Upside/Downside: +740.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$52.34 million
• Net Margins: -5,142.56%
• Pretax Margin: -5,142.56%
• Return on Equity: -39.24%
• Return on Assets: -26.19%

Debt

• Debt-to-Equity Ratio: 0.18
• Current Ratio: 5.66
• Quick Ratio: 5.66

Sales & Book Value

• Annual Sales: $548 thousand
• Price / Sales: 42.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.24 per share
• Price / Book: 0.27

Miscellaneous

• Outstanding Shares: 71,110,000
• Free Float: 61,566,000
• Market Cap: $23.55 million
• Optionable: Optionable
• Beta: 0.08